Could a cancer drug tame kaposi sarcoma in HIV patients?
NCT ID NCT03601806
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase II trial tested the drug pomalidomide in 26 HIV-positive adults with Kaposi sarcoma, a type of skin cancer common in Sub-Saharan Africa. Pomalidomide works by boosting the immune system and blocking blood vessel growth that feeds tumors. Researchers measured how many participants responded to treatment and tracked side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pomalidomide (a drug that boosts the immune system and blocks tumor blood vessel growth)
What this could lead to
If successful, this could point toward a new treatment option for Kaposi sarcoma in people with HIV, especially in regions with limited access to standard therapies.
What could go wrong
This is a small, early-phase trial (Phase II) with only 26 participants, so results may not apply broadly. Side effects like serious toxicities are possible, and the drug may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SKIN KAPOSI SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moi University School of Medicine
Eldoret, Kenya
-
UNC Project Malawi
Lilongwe, Malawi
-
Uganda Cancer Institute
Kampala, Uganda